ArticleClinical cancer research : an official journal of the American Association for Cancer Research2011
HER2-affitoxin: a potent therapeutic agent for the treatment of HER2-overexpressing tumors.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 50 citations in OpenAlex.
- Manufacture and evaluation of a HER2-positive breast cancer immunotoxin 4D5Fv-PE25.Microbial cell factories · 2023Article
- Engineering Saccharomyces cerevisiae for the production and secretion of Affibody molecules.Microbial cell factories · 2022Article
- Self-Assembled Nanomicelles of Affibody-Drug Conjugate with Excellent Therapeutic Property to Cure Ovary and Breast Cancers.Nano-micro letters · 2021Article
- Fighting Cancer with Bacteria and Their Toxins.International journal of molecular sciences · 2021Review
- Purification and In Vitro Evaluation of an Anti-HER2 Affibody-Monomethyl Auristatin E Conjugate in HER2-Positive Cancer Cells.Biology · 2021Article
- Generation of a novel affibody molecule targeting Chlamydia trachomatis MOMP.Applied microbiology and biotechnology · 2021Article
- HER2-Specific Pseudomonas Exotoxin A PE25 Based Fusions: Influence of Targeting Domain on Target Binding, Toxicity, and In Vivo Biodistribution.Pharmaceutics · 2020Article
- Novel EBV LMP-2-affibody and affitoxin in molecular imaging and targeted therapy of nasopharyngeal carcinoma.PLoS pathogens · 2020Article
- HER2-Specific Targeted Toxin DARPin-LoPE: Immunogenicity and Antitumor Effect on Intraperitoneal Ovarian Cancer Xenograft Model.International journal of molecular sciences · 2019Article
- Evaluation of HER2-specific peptide ligand for its employment as radiolabeled imaging probe.Scientific reports · 2018Article
- A novel HPV16 E7-affitoxin for targeted therapy of HPV16-induced human cervical cancer.Theranostics · 2018Article
- Design and In Vitro Evaluation of a Cytotoxic Conjugate Based on the Anti-HER2 Affibody Fused to the Fc Fragment of IgG1.International journal of molecular sciences · 2017Article
- Affibody molecules as engineered protein drugs.Experimental & molecular medicine · 2017Review
- A Conjugate Based on Anti-HER2 Diaffibody and Auristatin E Targets HER2-Positive Cancer Cells.International journal of molecular sciences · 2017Article
- Enhanced lysis by bispecific oncolytic measles viruses simultaneously using HER2/neu or EpCAM as target receptors.Molecular therapy oncolytics · 2016Article
- Role of ErbB Receptors in Cancer Cell Migration and Invasion.Frontiers in pharmacology · 2015Review
- Receptor-directed chimeric toxins created by sortase-mediated protein fusion.Molecular cancer therapeutics · 2013Article
- New developments in the treatment of HER2-positive breast cancer.Breast cancer (Dove Medical Press) · 2012Article
- Affibody-DyLight conjugates for in vivo assessment of HER2 expression by near-infrared optical imaging.PloS one · 2012Article
- Cellular effects of HER3-specific affibody molecules.PloS one · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
Abstract
purposeCancers overexpressing the HER2/neu gene are usually more aggressive and are associated with poor prognosis. Although trastuzumab has significantly improved the outcome, many tumors do not respond or acquire resistance to current therapies. To provide an alternative HER2-targeted therapy, we have developed and characterized a novel recombinant protein combining an HER2-specific Affibody and modified Pseudomonas aeruginosa exotoxin A (PE 38), which, after binding to HER2, is internalized and delivered to the cytosol of the tumor cell, where it blocks protein synthesis by ADP ribosylation of eEF-2. EXPERIMENTAL
designThe effect of the Affitoxin on cell viability was assessed using CellTiter-Glo (Promega). To assess HER2-specific efficacy, athymic nude mice bearing BT-474 breast cancer, SK-OV-3 ovarian cancer, and NCI-N87 gastric carcinoma xenografts were treated with the Affitoxin (HER2- or Tag-specific), which was injected every third day. Affitoxin immunogenicity in female BALB/c mice was investigated using standard antibody production and splenocyte proliferation assays.
resultsIn vitro experiments proved that HER2-Affitoxin is a potent agent that eliminates HER2-overexpressing cells at low picomolar concentrations. Therapeutic efficacy studies showed complete eradication of relatively large BT-474 tumors and significant effects on SK-OV-3 and NCI-N87 tumors. HER2-Affitoxin cleared quickly from circulation (T(1/2) < 10 minutes) and was well tolerated by mice at doses of 0.5 mg/kg and below. Immunogenicity studies indicated that HER2-Affitoxin induced antibody development after the third injected dose.
conclusionsOur findings showed that HER2-Affitoxin is an effective anticancer agent and a potential candidate for clinical studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.